Patents Examined by Bethany P Barham
  • Pharmaceutical composition comprising licarbazepine acetate
    Patent number: 10912781
    Abstract: A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: February 9, 2021
    Assignee: BIAL-Portela & C.A., S.A.
    Inventors: Teöfilo Cardoso de Vasconcelos, Ricardo Jorge dos Santos Lima, Rui Cerdeira de Campos Costa
  • Compositions and method for storing liquid biospecimens
    Patent number: 10905113
    Abstract: This disclosure describes a lyoprotectant matrix, compositions including the lyoprotectant matrix and methods for storing a liquid biospecimen using the lyoprotectant matrix. Generally, the lyoprotectant matrix includes a non-woven web having fibers having, as components, at least one lyoprotective carbohydrate and at least one polymer. The matrix further possesses an apparent pore size of 0.1 ?m to 500 ?m.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: February 2, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Alptekin Aksan, Morwena Jane V. Solivio, Marcus Kramer, Rebekah Less
  • Thermoplastic materials having beneficial properties and processes for providing the same
    Patent number: 10897895
    Abstract: Methods of providing sustained sterilization of thermoplastics; providing thermoplastics that have the capacity to dispense sodium fluoride, and, a method of providing sustained sterilization of thermoplastics and providing thermoplastics that have the capacity to dispense sodium fluoride, both from the same thermoplastic article.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: January 26, 2021
    Assignee: QuadSil, Inc.
    Inventors: John D. Blizzard, Joan McMahon, Michael Silver
  • Programmable pharmaceutical compositions for chrono drug release
    Patent number: 10898431
    Abstract: The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. The programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, gastric motility, and volume and viscosity of gastric fluid. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm, e.g., that matches the human circadian rhythm of a condition's symptoms and/or of the individual being treated in the application of the therapy to optimize therapeutic outcome and minimize side effects.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: January 26, 2021
    Assignee: KASHIV BIOSCIENCES, LLC
    Inventors: Siva Ram Kiran Vaka, Paras Jariwala, Jaydeep Vaghashiya, Atsawin Thongsukmak, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah
  • Pharmaceutical composition containing antifungal agent as active ingredient
    Patent number: 10898470
    Abstract: The present invention provides a technique that allows a pharmaceutical composition, preferably for external use, containing luliconazole or the like to contain luliconazole or the like at a high concentration, and suppresses the precipitation thereof over time. The present invention uses a polyethylene glycol having an average molecular weight of 380 to 420 represented by a formula HOCH2(CH2OCH2)nCH2OH (where n is an integer), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone in combination with the luliconazole or the like.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: January 26, 2021
    Assignee: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Masahiro Ito, Kiyotaka Matsui, Masami Inuma
  • Pharmaceutical compositions comprising a fumaric acid ester and method for the preparation thereof
    Patent number: 10894026
    Abstract: The present invention relates to a delayed release pharmaceutical composition comprising a fumaric acid ester such as Dimethyl fumarate in the form of gastro-resistant tablets filled into hard gelation capsule.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: January 19, 2021
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthymios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Morfis Abatzis, Manolis Fousteris
  • Methods for treating eye disorders using ocular implants
    Patent number: 10881609
    Abstract: The present disclosure generally relates to local therapies for the eye and, more particularly, to shaped controlled-release ocular implant devices, including methods for making and using such devices, for delivery of therapeutic agents to the eye. A molded two-layer ocular implant comprises a therapeutic agent for treatment or prevention of a disorder of the eye. The implant comprises a polymer layer and a silicone adhesive layer with a therapeutic agent interspersed therein and joined to the polymer layer. This implant is for placement in the sub-Tenon's space of the eye and provides sustained release of the therapeutic agent during the treatment or prevention of the disorder of the eye.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: January 5, 2021
    Assignee: Retina Foundation Of The Southwest
    Inventor: Karl Csaky
  • Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
    Patent number: 10874689
    Abstract: Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: December 29, 2020
    Assignee: Galleon Labs LLC
    Inventor: Gary S. Hahn
  • Therapeutic textile articles and methods of use
    Patent number: 10874547
    Abstract: The present invention relates generally to therapeutic articles comprised of carbonaceous blend textile materials comprising yarns having about 25 to 100 weight % carbonaceous fiber and about 0 to 75 weight % fiber made of polyester, nylon, rayon, lyocell, cellulose, wool, silk, linen, bamboo, m-aramid, p-aramid, modacrylic, novoloid, melamine, regenerated cellulose, polyvinyl chloride, antistatic fiber, poly(p-phenylene benzobisoxazole) (PBO), polybenzimidazole (PBI), polysulphonamide (PSA), and combinations thereof, or other fibers not listed that are capable of being made into yarn and textile fabrics that are knit, woven, or nonwoven, and wherein the fabric has a weight from about 3 oz/yd2 to about 20 oz/yd2.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: December 29, 2020
    Inventors: David L. Burge, Catherine M. Burge
  • Phenothiazine diaminium salts and their use
    Patent number: 10864216
    Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: December 15, 2020
    Assignee: WisTa Laboratories, Ltd.
    Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
  • Hair conditioning composition comprising cyclic compounds and compounds having at least three head groups
    Patent number: 10857086
    Abstract: Disclosed is a hair conditioning composition comprising: a cationic surfactant; a high melting point fatty compound; a cyclic compound selected from the group consisting of a vitamin B3 compound, a xanthine compound, a salicylic acid ester, and mixtures thereof; a compound having at least three large head groups; and an aqueous carrier. The composition of the present invention provides improved hair manageability.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 8, 2020
    Assignee: The Procter and Gamble Company
    Inventor: Mui Siang Soh
  • Ophthalmic composition
    Patent number: 10842875
    Abstract: The inventive ophthalmic composition comprises: (A) polyvinyl pyrrolidone K90; and (B) at least one selected from the group consisting of an oil component, a grease component and polyethylene glycol. The ophthalmic composition alleviates a sticky sensation to ensure an excellent use sensation.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: November 24, 2020
    Assignee: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Aki Kiyomiya, Takahiro Kurose, Atsuko Nakata, Xiang Zheng
  • Cosmetic composition comprising white rose flower extract for skin whitening and improving skin wrinkle
    Patent number: 10842727
    Abstract: Provided is a functional cosmetic composition of white rose extract and a gartanin derivative compound isolated therefrom, and specifically, to a cosmetic composition for skin whitening and skin wrinkle alleviation containing, as active ingredients, white rose petal extract and gartanin derivative compounds isolated therefrom. The white rose extract and gartanin derivative compound, according to the present invention, are safe without causing side effects on the skin, prevent melanin production through a mechanism inhibiting tyrosinase activity, thereby having a whitening effect, and exhibit a wrinkle alleviation effect by a mechanism inhibiting MMP-1 activity, and thus the composition, of the present invention, containing the same as active ingredients, can be utilized as a material for functional cosmetics for skin whitening and wrinkle alleviation without causing skin irritation.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: November 24, 2020
    Assignees: GANGNEUNG-WONGJU NATIONAL UNIVERSITY INDUSTRY ACADEMY COOPERATION GROUP, CHUNGBUK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Yun-Bae Kim, Seong-Soo Joo
  • Compositions of nitrates and methods of use thereof
    Patent number: 10842813
    Abstract: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 24, 2020
    Assignee: HEARTBEET LTD
    Inventors: Jon Lundberg, Eddie Weitzberg
  • Compositions of nitrates and methods of use thereof
    Patent number: 10835555
    Abstract: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 17, 2020
    Assignee: HEARTBEET LTD
    Inventors: Jon Lundberg, Eddie Weitzberg
  • Disinfectant composition
    Patent number: 10827752
    Abstract: This invention relates to disinfectant compositions comprising a first active ingredient comprising a source of acetyl radicals, and a second active ingredient comprising a source of peroxygen, the composition being soluble in water to provide a solution of peracetic acid.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: November 10, 2020
    Inventor: Peter Finan
  • Compositions of nitrates and methods of use thereof
    Patent number: 10821132
    Abstract: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 3, 2020
    Assignee: HEARTBEET LTD
    Inventors: Jon Lundberg, Eddie Weitzberg
  • Method of sterilization of microparticles
    Patent number: 10821200
    Abstract: Methods of sterilizing microparticles using a porous solid matrix which allows penetration of a sterilizing gas such as EtO to pass through are disclosed. The methods also include preparing a suspension of the sterilized microparticles by reconstituting the porous matrix containing the microparticles.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: November 3, 2020
    Assignee: HYALO TECHNOLOGIES, LLC
    Inventor: Shalabh Jain
  • Elastic biopolymer and use as a tissue adhesive
    Patent number: 10814032
    Abstract: The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: October 27, 2020
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Ali Khademhosseini, Nasim Annabi, Alexander Assmann
  • Vaccine compositions
    Patent number: 10806783
    Abstract: The present invention relates to the use of an excipient which is a compound of formula (I) or a physiologically acceptable salt or ester thereof: wherein: R1 represents C1-6alkyl; R2 represents hydrogen or C1-6alkyl; and R3 represents C1-6alkyl, for increasing the immunogenicity of an influenza antigen, which use comprises (a) freezing, (b) heat-treating, and/or (c) freeze-drying an aqueous composition comprising the influenza antigen and the excipient.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: October 20, 2020
    Assignee: Stabilitech Biopharma Ltd
    Inventor: Jeffrey Drew